Cargando…

Analysis of the Complete Open Reading Frame of Genotype 2b Hepatitis C Virus in Association with the Response to Peginterferon and Ribavirin Therapy

BACKGROUND AND AIMS: Patients infected with genotype 2b hepatitis C virus (HCV) generally can achieve favorable responses to pegylated-interferon plus ribavirin therapy (PEG-IFN/RBV). However, a proportion of patients show poorer responses and the correlation between viral sequence variation and tre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kadokura, Makoto, Maekawa, Shinya, Sueki, Ryota, Miura, Mika, Komase, Kazuki, Shindo, Hiroko, Amemiya, Fumitake, Uetake, Tomoyoshi, Inoue, Taisuke, Sakamoto, Minoru, Nakagawa, Mina, Sakamoto, Naoya, Watanabe, Mamoru, Enomoto, Nobuyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174186/ https://www.ncbi.nlm.nih.gov/pubmed/21935415 http://dx.doi.org/10.1371/journal.pone.0024514

Ejemplares similares

Semiannual Imaging Surveillance Is Associated with Better Survival in Patients with Non-B, Non-C Hepatocellular Carcinoma
por: Shindo, Kuniaki, et al.
Publicado: (2015)

Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C
por: Masaki, Naohiko, et al.
Publicado: (2014)

Deep Sequencing of Cancer-Related Genes Revealed GNAS Mutations to Be Associated with Intraductal Papillary Mucinous Neoplasms and Its Main Pancreatic Duct Dilation
por: Takano, Shinichi, et al.
Publicado: (2014)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Chronic HCV treatment with peginterferon-ribavirin and severe tuberculosis re-activation
por: Manfredi, Roberto, et al.
Publicado: (2010)

Is peginterferon and ribavirin therapy effective in Korean patients with chronic hepatitis C?
por: Jung, Young Kul, et al.
Publicado: (2013)

Relationship between presarcopenia and event occurrence in patients with primary hepatocellular carcinoma
por: Takada, Hitomi, et al.
Publicado: (2020)

Utility of the simplified measurements of muscle mass in patients with gastrointestinal and chronic liver diseases
por: Takada, Hitomi, et al.
Publicado: (2020)

A meta-analysis that compares the use of either peginterferon-α2a or peginterferon-α2b plus ribavirin for HCV infection
por: Xiao, Nan, et al.
Publicado: (2010)

HBV preS deletion mapping using deep sequencing demonstrates a unique association with viral markers
por: Suzuki, Yuichiro, et al.
Publicado: (2019)

Next‐generation sequencing of endoscopically obtained tissues from patients with all stages of pancreatic cancer
por: Takano, Shinichi, et al.
Publicado: (2022)

Hepatic Amyloidosis with an Extremely High Stiffness Value on Magnetic Resonance Elastography
por: MATSUDA, Shuya, et al.
Publicado: (2016)

Usefulness of Cell‐Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy
por: Muraoka, Masaru, et al.
Publicado: (2021)

Target sequencing of cancer-related genes in early esophageal squamous neoplasia resected by endoscopic resection in Japanese patients
por: Kobayashi, Shoji, et al.
Publicado: (2018)

Peginterferon alpha and ribavirin combination therapy in patients with hepatitis C virus-related liver cirrhosis
por: Kim, Kyung Hoon, et al.
Publicado: (2011)

Durability of a sustained virologic response in patients with chronic hepatitis C treated with peginterferon and ribavirin
por: Kim, Kyung-Ah
Publicado: (2011)

Revisiting the Stopping Rule for Hepatitis C Genotype 1 Patients Treated with Peginterferon Plus Ribavirin
por: Yu, Ming-Lung, et al.
Publicado: (2012)

Regional differences in hepatitis C treatment with peginterferon and ribavirin in Japan: a retrospective cohort study
por: Ide, Kazuki, et al.
Publicado: (2016)

Daclatasvir combined with peginterferon-α and ribavirin for the treatment of chronic hepatitis C: a meta-analysis
por: Peng, Qin, et al.
Publicado: (2016)

Extravasation and fluid collection on computed tomography imaging in patients with colonic diverticular bleeding
por: Takada, Hitomi, et al.
Publicado: (2020)

A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C
por: Flisiak, Robert, et al.
Publicado: (2016)

Digital next‐generation sequencing of cell‐free DNA for pancreatic cancer
por: Takano, Shinichi, et al.
Publicado: (2021)

Sarcoidosis with Both Plaques and Subcutaneous Nodules Associated with Combination Therapy with Peginterferon α-2a and Ribavirin
por: Kondo, M., et al.
Publicado: (2011)

Efficacy of peginterferon and ribavirin is associated with the IL28B gene in Korean patients with chronic hepatitis C
por: Jeong, Seok Hoo, et al.
Publicado: (2012)

Efficacy and Safety of Low-Dose Peginterferon Alpha-2a Plus Ribavirin on Chronic Hepatitis C
por: Yan, Zehui, et al.
Publicado: (2012)

Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C
por: Kuo, Ming-Te, et al.
Publicado: (2014)

Stepwise correlation of TP53 mutations from pancreaticobiliary maljunction to gallbladder carcinoma: a retrospective study
por: Kawakami, Satoshi, et al.
Publicado: (2021)

Form-Vessel Classification of Cholangioscopy Findings to Diagnose Biliary Tract Carcinoma’s Superficial Spread
por: Fukasawa, Yoshimitsu, et al.
Publicado: (2020)

Efficacy and Tolerability of Peginterferon α-2a and Peginterferon α-2b, Both plus Ribavirin, for Chronic Hepatitis C: A Meta-Analysis of Randomized Controlled Trials
por: Yang, Zongguo, et al.
Publicado: (2013)

Delayed Viral Clearance after 6-Week Treatment with Peginterferon Plus Ribavirin in a Patient with Chronic Hepatitis C Virus Genotype 1b
por: Sato, Akira, et al.
Publicado: (2016)

Management of rare side effects of peginterferon and ribavirin therapy during hepatitis C treatment: a case report
por: EL-Atrebi, Kamal, et al.
Publicado: (2009)

Roles of ITPA and IL28B Genotypes in Chronic Hepatitis C Patients Treated with Peginterferon Plus Ribavirin
por: Miyamura, Tatsuo, et al.
Publicado: (2012)

Alanine Aminotransferase Elevation during Peginterferon Alpha-2a or Alpha-2b plus Ribavirin Treatment
por: Nakamura, Masato, et al.
Publicado: (2013)

Incidence of and risk factors for thyroid dysfunction during peginterferon α and ribavirin treatment in patients with chronic hepatitis C
por: Hwang, Yong, et al.
Publicado: (2015)

Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis
por: Lawitz, Eric, et al.
Publicado: (2015)

Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C
por: Jung, Chang Ho, et al.
Publicado: (2016)

Differences in clinical outcomes among hepatitis C genotype 1-infected patients treated with peginterferon alpha-2a or peginterferon alpha-2b plus ribavirin: a meta-analysis
por: Druyts, Eric, et al.
Publicado: (2012)

Assessment of the Efficacy of Reducing Peginterferon Alfa-2a and Ribavirin Dose on Virologic Response in Koreans with Chronic Hepatitis C
por: Kwon, Jung Hyun, et al.
Publicado: (2009)

Prediction of Treatment Week Eight Response & Sustained Virologic Response in Patients Treated with Boceprevir Plus Peginterferon Alfa and Ribavirin
por: Thompson, Alex, et al.
Publicado: (2014)

Highly effective peginterferon α-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
por: Yang, Suh Yoon, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fj17a1lmvd0700p2ad28id3h9t